Zacks Investment Research on MSN

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer PFE will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales ...
Healio

Antivirals reduce long COVID incidence at 90 days in patients with rheumatic diseases

Patients with autoimmune and rheumatic diseases who received antiviral therapy for COVID-19 demonstrated reduced incidence of ...
ABC 7 Chicago

Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...
Zacks.com on MSN

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset ...
TipRanks on MSN

Pfizer’s PAXLOVID Study: Real-World Insights on COVID-19 Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, ...